Artiva Biotherapeutics, Inc. (ARTV)
NGM · Healthcare · Biotechnology
Closing price as of 2026-08-12 · Source: TEK2day Finance
Key Metrics
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -22.9M | -21.9M | -24.4M | -26.9M |
| Net Income | -21.5M | -20.8M | -23.5M | -25.0M |
| Diluted EPS | $-0.88 | $nan | $-0.95 | $-0.63 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 4.9M | 33.5M | 251K | 0.00 |
| Operating Income | -59.8M | -30.7M | -67.3M | -89.8M |
| Net Income | -61.0M | -32.8M | -58.2M | -83.9M |
| Diluted EPS | $-6.51 | $-1.41 | $-5.81 | $nan |